UK markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3000+0.1600 (+5.10%)
At close: 4:00PM EST

3.3000 0.00 (0.00%)
After hours: 5:59PM EST

Full screen
Trade prices are not sourced from all markets
Previous close3.1400
Open3.2000
Bid3.2900 x 3000
Ask3.3500 x 1300
Day's range2.9100 - 3.3000
52-week range0.8800 - 9.0200
Volume3,744,665
Avg. volume3,983,990
Market cap280.201M
Beta (5Y monthly)3.05
PE ratio (TTM)N/A
EPS (TTM)-1.2060
Earnings date06 May 2021 - 11 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.71
  • Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript
    Motley Fool

    Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation fourth-quarter and year-end 2020 financial results and corporate update conference call. Good morning, and thank you for joining the Arbutus Biopharma fourth-quarter 2020 conference call and webcast. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer.

  • Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

    Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?
    Zacks

    Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?

    Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.